

# Protein Kinase C Theta Type - Pipeline Review, H1 2020

<https://marketpublishers.com/r/P0AF39F73097EN.html>

Date: January 2020

Pages: 37

Price: US\$ 3,500.00 (Single User License)

ID: P0AF39F73097EN

## Abstracts

Protein Kinase C Theta Type - Pipeline Review, H1 2020

### SUMMARY

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Protein kinase C theta (PKC-?) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-costimulated T-cells, is required for the activation of NF-kappa-B and JUN. It plays an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. It mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1 which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway.

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 3 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Infectious Disease and Metabolic Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Rheumatoid Arthritis, Autoimmune Disorders, Ewing Sarcoma, Heart Transplant Rejection, Inflammation, Insulin Resistance, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Metastatic Breast Cancer, Obesity, Prostate Cancer and Type 2 Diabetes.

The latest report Protein Kinase C Theta Type - Pipeline Review, H1 2020, outlays comprehensive information on the Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)

The report reviews Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects

The report assesses Protein Kinase C Theta Type (nPKC Theta or PRKCQ or

EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Overview

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Companies  
Involved in Therapeutics Development

Astellas Pharma Inc

Bristol-Myers Squibb Co

CompleGen Inc

EpiAxis Therapeutics Pty Ltd

HotSpot Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Drug Profiles

AS-2521780 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-90005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGX-0471 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGX-1079 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
englerin A - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
EPI-110 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecule to Inhibit PKC-Theta for Inflammation - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecules for Ewing Sarcoma - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecules to Inhibit PRKCQ for Autoimmune Disorders - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Dormant Products  
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Discontinued Products  
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Product Development Milestones  
Featured News & Press Releases  
Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Astellas Pharma Inc, H1 2020

Pipeline by Bristol-Myers Squibb Co, H1 2020

Pipeline by CompleGen Inc, H1 2020

Pipeline by EpiAxis Therapeutics Pty Ltd, H1 2020

Pipeline by HotSpot Therapeutics Inc, H1 2020

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Astellas Pharma Inc

Bristol-Myers Squibb Co

CompleGen Inc

EpiAxis Therapeutics Pty Ltd

HotSpot Therapeutics Inc

Takeda Pharmaceutical Co Ltd

## I would like to order

Product name: Protein Kinase C Theta Type - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/P0AF39F73097EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P0AF39F73097EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970